15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Minerva Neurosciences Inc, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $7.00 to $14.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $10.50 sits 150% above the current $4.21. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.01 next quarter toward $-0.80 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Minerva Neurosciences Inc.
As of Jul, 1 of 2 firms rate NERV a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NERV EPS & revenue forecast
EPS · NEXT QUARTER
$-0.01
Range $-0.01 – $-0.01 · 1 analysts
Next period, 1 analysts expect Minerva Neurosciences Inc to earn $-0.01 a share (range $-0.01 – $-0.01), versus — a year earlier. Full-year consensus is $-0.20, growing to $-0.80 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Minerva Neurosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NERV.
#1
Jason Butler
JMP Securities · Rank #22
Buy
$14.00+232.9% to target
Overall win rate
57%
+ Follow
#2
Douglas Tsao
HC Wainwright & Co. · Rank #212
Hold
$7.00+66.5% to target
Overall win rate
35%
+ Follow
#3
JN
Jason N. Butler
Citizens
Buy
$14.00+232.9% to target
Coverage
—
+ Follow
#4
Andrew Tsai
Jefferies
Hold
$5.00+18.9% to target
Coverage
—
+ Follow
NERV stock forecast FAQ
What is NERV's average 12-month price target?+
The 2 analysts with a live target average $10.50 for Minerva Neurosciences Inc over the next 12 months, ranging from a $14.00 high to a $7.00 low.
Is NERV stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NERV?+
The Street-high target is $14.00 (Citizens), and the Street-low is $7.00 (HC Wainwright & Co.). The average of all 2 active targets is $10.50.
How many Wall Street analysts cover NERV?+
2 analysts have an active rating on Minerva Neurosciences Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering NERV?+
Among analysts who currently cover NERV, Jason Butler of JMP Securities has the strongest overall Quantellect track record (Rank #22). Their current call is Buy with a $14.00 target.
What is Minerva Neurosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.01 per share (range $-0.01 – $-0.01) across 1 analysts. Full-year EPS is projected at $-0.20, rising to $-0.80 the following year.
How much revenue is Minerva Neurosciences Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading NERV lately?+
As of Jul, 1 of 2 firms rate NERV a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NERV calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
